Margit Holzer, PhD, owner of Ulysse Consult, is chairing a session on the future of bioprocessing at this year’s Bioprocessing Summit Europe. She talks to GEN about new molecules, technologies, and products.
Holzer: We need to think about the new biological products we must work with. Products, such as CAR-T, plasmids, viral vectors and RNA or DNA vaccines, are larger and much more complex. We need adapted and different production systems to make these products, increase their productivity, and speed up development.
Furthermore, I see productivity improvements in the production of existing products, such as monoclonal antibodies and recombinant insulin.